ASTRO

ASTRO $ASTRO 2022: Three week hypo-fractionated whole breast irradiation (WBI) with concurrent boost not inferior to conventional WBI with a sequential boost following lumpectomy for high-risk, early-stage breast cancer$

ASTRO 2022: Three week hypo-fractionated whole breast irradiation (WBI) with concurrent boost not inferior to conventional WBI with a sequential boost following lumpectomy for high-risk, early-stage breast cancer

November 1, 2022

Results from the analysis of the NRG Oncology RTOG 1005 clinical trial data concluded that…

ASTRO

ASTRO 2022: Lower prostate cancer screening rates associated with subsequent increase in advanced cancers

November 1, 2022

In the face of conflicting evidence over the risks and benefits of routine prostate cancer…

ASTRO

ASTRO 2022: Three-week course of radiation safe and effective for patients with early-stage breast cancer

November 1, 2022

A three-week course of radiation therapy is as safe and effective as four to six…

ASTRO

Sexual side effects of cancer treatment often unaddressed with female patients

October 28, 2022

A new study finds that sexual side effects of cancer treatment are discussed far less…

Browsing: ASTRO

ASTRO 2022: Three week hypo-fractionated whole breast irradiation (WBI) with concurrent boost not inferior to conventional WBI with a sequential boost following lumpectomy for high-risk, early-stage breast cancer

ASTRO 2022: Lower prostate cancer screening rates associated with subsequent increase in advanced cancers

ASTRO 2022: Three-week course of radiation safe and effective for patients with early-stage breast cancer

Sexual side effects of cancer treatment often unaddressed with female patients